Literature DB >> 16221704

The importance of standardization of creatinine in the implementation of guidelines and recommendations for CKD: implications for CKD management programmes.

Wim Van Biesen1, Raymond Vanholder, Nic Veys, Francis Verbeke, Joris Delanghe, Dirk De Bacquer, Norbert Lameire.   

Abstract

BACKGROUND: In an attempt to reduce late referral and to improve the care of patients with chronic kidney disease (CKD), different organizations have issued guidelines on when to refer patients to the nephrologist. Most suggest referral of patients with a GFR below 60 ml/min/1.73 m2, and demand referral if the GFR is below 30 ml/min/1.73 m2. It is recommended to use the abbreviated MDRD equation to estimate GFR. This formula is, however, sensitive to the creatinine assay methodology. In addition, the impact of the implementation of such guidelines on the nephrology practice has never been evaluated. This study (i) identifies the true burden of CKD in a population and simulates the effects of a 100% implementation of the guidelines on the nephrology work load, and (ii) evaluates the validity of the estimated GFR using the abbreviated MDRD formula when routinely provided.
METHODS: Different laboratories (both hospital and private) in our region were asked to report on all the serum creatinine values performed during the first week of December 2004. If patients had more than one determination, only the lowest serum creatinine value was retained. Patients already known to a nephrology unit were not included. GFR was calculated using the abbreviated MDRD, using the serum creatinine as reported by these laboratories, or after correction to the MDRD-standard using different published equations.
RESULTS: 20,108 patients, with a mean age of 53.4+/-16.2 years, 48% females, had at least one serum creatinine determination in the observation period. According to the K/DOQI CKD classification, 20.2, 1.6 and 0.8% of females and 13.3, 1.6 and 0.6% of males were in stage 3, 4 and 5, respectively, when the abbreviated MDRD formula was used with the serum creatinine value as reported by the laboratories. Important differences in classifications were obtained when the different correction formulae for creatinine were applied. According to the current recommendations, this would lead to a mandatory referral of 1650-2400 CKD stage 4 patients per 100 000 inhabitants and a suggested referral of another 4100-15 360 CKD stage 3 patients per 100,000 inhabitants to a nephrology unit.
CONCLUSION: Implementation of the current guidelines for referral of CKD patients to nephrologists would lead to an overload of the nephrology care capacities. Large differences in estimated GFRs with different corrections for serum creatinine are observed, resulting in important CKD classification differences. Standardization of serum creatinine assays is mandatory before guidelines, and especially the routine provision of the estimated GFR by the abbreviated MDRD formula, can be implemented in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16221704     DOI: 10.1093/ndt/gfi185

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  16 in total

Review 1.  How to measure renal function in clinical practice.

Authors:  Jamie Traynor; Robert Mactier; Colin C Geddes; Jonathan G Fox
Journal:  BMJ       Date:  2006-10-07

2.  Natural history of CKD stage 4 and 5 patients following referral to renal management clinic.

Authors:  Ai-Hua Zhang; Paul Tam; Denise LeBlanc; Hui Zhong; Christopher T Chan; Joanne M Bargman; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2009-07-04       Impact factor: 2.370

3.  Cystatin C as a marker of acute kidney injury in the emergency department.

Authors:  Karina Soto; Silvia Coelho; Bruno Rodrigues; Henrique Martins; Francisca Frade; Stela Lopes; Luis Cunha; Ana Luisa Papoila; Prasad Devarajan
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-24       Impact factor: 8.237

Review 4.  Standardization in laboratory medicine: Adoption of common reference intervals to the Croatian population.

Authors:  Zlata Flegar-Meštrić; Sonja Perkov; Andrea Radeljak
Journal:  World J Methodol       Date:  2016-03-26

Review 5.  Calibration and precision of serum creatinine and plasma cystatin C measurement: impact on the estimation of glomerular filtration rate.

Authors:  Pierre Delanaye; Etienne Cavalier; Jean-Paul Cristol; Joris R Delanghe
Journal:  J Nephrol       Date:  2014-04-08       Impact factor: 3.902

6.  Recalibration of cystatin C using standardized material in Siemens nephelometers.

Authors:  George J Schwartz; Christopher Cox; Jesse C Seegmiller; Paula S Maier; Donna DiManno; Sue L Furth; Bradley A Warady; Alvaro Munoz
Journal:  Pediatr Nephrol       Date:  2019-11-03       Impact factor: 3.714

7.  Establishing a renal management clinic in China: initiative, challenges, and opportunities.

Authors:  Ai-Hua Zhang; Hui Zhong; Wen Tang; Shao-Yan Chen; Lian He; Song Wang; Chun Yan Su; Xin-Hong Lu; Tao Wang
Journal:  Int Urol Nephrol       Date:  2008-09-03       Impact factor: 2.370

8.  Estimating glomerular filtration rate: Cockcroft-Gault and Modification of Diet in Renal Disease formulas compared to renal inulin clearance.

Authors:  Rossini Botev; Jean-Pierre Mallié; Cecilé Couchoud; Otto Schück; Jean-Pierre Fauvel; Jack F M Wetzels; Nelson Lee; Natale G De Santo; Massimo Cirillo
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 8.237

9.  Elevated uric acid increases the risk for kidney disease.

Authors:  Rudolf P Obermayr; Christian Temml; Georg Gutjahr; Maarten Knechtelsdorfer; Rainer Oberbauer; Renate Klauser-Braun
Journal:  J Am Soc Nephrol       Date:  2008-09-17       Impact factor: 10.121

10.  Accuracy and limitations of equations for predicting the glomerular filtration rate during follow-up of patients with non-diabetic nephropathies.

Authors:  Guy Rostoker; Pierre Andrivet; Isabelle Pham; Mireille Griuncelli; Serge Adnot
Journal:  BMC Nephrol       Date:  2009-06-25       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.